PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN). Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from Amgen and $110 million from Royalty Pharma in aggregate development, regulatory, and sal ..read more

SAN DIEGO--(BUSINESS WIRE)--$CLDI #immunotherapy--Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the acceptance of three abstracts that will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31-June 4, 2024, in Chicago, Illinois. The posters will include an update from a City of Hope-led Phase 1 study of Calidi's CLD-101 program, focusing on the treatment of recurrent high-grade glioma, n ..read more

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI) in Rensselaer, New York, today announced receipt of a $4 million grant from the California Institute for Regeneration Medicine (CIRM) to support the ongoing Phase 1/2a study (NCT04627428) of RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration (dry AMD). The funding will accelerate manufacturing and clinical activities based in California. RPESC-RPE-4W is a cell product derived from adult r ..read more

New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca’s innovation and commitment to transform care in COPD WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyang ..read more

Global contract research organization honored as top outsourcing partner, earning high marks in several categories from Industry Standard Research RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--#CROLeader--Worldwide Clinical Trials (Worldwide), a leading global, full-service contract research organization (CRO), has been recognized for excellence in all five categories in the 2024 CRO Leadership Awards, based on primary market research from Industry Standard Research (ISR) Reports and presented by Clinical Leader and Life Science Leader magazines. This marks the 11th consecutive year that Wor ..read more

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences: Wells Fargo Virtual Private Biotech Symposium Format: 1x1 Investor Meetings Date: May 6, 2024 Location: Virtual Capital One Biotech - Life Sciences Disruptors Event Format: Panel Discussion on “The Next Wave of mRNA and Gene Correction Therapeutics” Date: May 14, 2024 Time: 1:45 p.m. ET Location: New York Vi ..read more

After a 25-year-long search, a new sequencing technique has helped researchers pinpoint the genetic cause of SCA4, a rare movement disorder. Spinocerebellar ataxia 4 (SCA4) is a rare genetic condition that severely impacts the lives of those affected by the disease. Like many other rare diseases, there is no known cure for SCA4, and until now, no known cause. Now, after 25 years of searching, a multi-institutional group of researchers led by a team at the University of Utah (UT, USA) has discovered the genetic difference that causes SCA4, providing families with much-needed answers ..read more

APOLLOE4 Phase 3 Trial Subjects Who Completed 78 Weeks of Treatment Offered Enrollment in Long-Term Extension Study to Provide Insights into Effect of ALZ-801 on Disease Progression and Additional Safety and Tolerability Data Phase 2 Biomarker Trial Subjects Who Completed 156 Weeks of Treatment Offered Enrollment in 52-Week Extension to Support Biomarker-Enabled Indication Expansion to Two Thirds of all AD Patients Carrying APOE4 Gene Array of Cutting-Edge Fluid and Imaging Biomarkers Deployed to Assess Impact of ALZ-801 Tablet on Alzheimer’s Pathology Fully Enrolled Pivotal APOLLOE4 Phase 3 ..read more

Ad hoc announcement pursuant to Art. 53 LR Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified Glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients not benefitting from current antipsychotic treatments Next step: Potentially pivotal, Phase III, one-year, randomized, double-blind, placebo-controlled trial in treatment resistant schizophrenia (TRS) International conference call today at 3:00 PM CET/9:00 AM ET MILAN--(BUSINESS WIRE)--$NWRN #schizophrenia--Newron Pharmaceuti ..read more

-Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief- BERWYN, Pa.--(BUSINESS WIRE)--#pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for a Maximum Tolerated Dose (MTD) study in Sprague-Dawley Rats for Probudur™. Probudur is Virpax’s injectable long-acting liposomal bupivacaine formulation that is injected at the woun ..read more